AstraZeneca
AZ and BMS diabetes drug needs more data
January 20, 2012Research and Development, Sales and Marketing AstraZeneca, BMS, FDA approvals, diabetes
AstraZeneca and Bristol-Myers Squibb must supply more data on their diabetes treatment dapagliflozin, the FDA says.Currently being developed as monotherapy, …
AstraZeneca looks for new partners to bolster pipeline
January 16, 2012Business Services, Research and Development, Sales and Marketing AstraZeneca, BMS
AstraZeneca has used a recent healthcare conference in San Francisco to call for new drug development partners. Speaking at the …
AstraZeneca does data deal
January 13, 2012Sales and Marketing AstraZeneca, IMS Health, data
AstraZeneca has signed a deal with an information company in a bid to improve the data it has on how …
AstraZeneca leaks confidential information
January 9, 2012Sales and Marketing AstraZeneca, data leak
There have been red faces at AstraZeneca after the company sent confidential information to analysts by mistake. It was forced …
AstraZeneca to take Alzheimer’s drug into phase II
January 5, 2012Research and Development Alzheimer's, AstraZeneca, Targacept
AstraZeneca is to continue the development of Targacept’s AZD1446 as a treatment for Alzheimer’s disease.AZD1446 is a selective modulator of …
AstraZeneca takes option on new diabetes candidates
December 21, 2011Sales and Marketing AstraZeneca, diabetes
AstraZeneca and Prosidion, a subsidiary of Astellas have signed a deal giving AstraZeneca an exclusive option to acquire two diabetes …
AstraZeneca, Novo and Enlight sign collaborative research deal
December 20, 2011Research and Development, Sales and Marketing AstraZeneca, Enlight, Novo Nordisk
AstraZeneca and Novo Nordisk have linked up with a US biosciences firm in a bid to enhance their R&D operations. …
AstraZeneca posts drug failures, takes $382m hit
December 20, 2011Research and Development, Sales and Marketing AstraZeneca, depression, ovarian cancer
AstraZeneca has taken a major blow to its late stage pipeline, with one of its key cancer drugs now being …
Brilique recommended for use by Germany’s pricing watchdog
December 19, 2011Sales and Marketing AstraZeneca, Brilique, Plavix
Germany’s new pricing committee has said that AstraZeneca’s Brilique is a cost effective treatment for patients with a certain heart …
Lisa Anson appointed as president of AstraZeneca’s UK marketing
December 15, 2011Business Services, Manufacturing and Production, Medical Communications, Sales and Marketing AstraZeneca, Lisa Anson
AstraZeneca has appointed Lisa Anson as its new president for the firm’s UK marketing company, effective 1 January 2012. Anson …
NICE rejects AstraZeneca’s breast cancer drug
December 14, 2011Sales and Marketing AstraZeneca, Faslodex, NICE
NICE has made its final decision not to recommended AstraZeneca’s breast cancer drug Faslodex, as it says the drug is …
AstraZeneca to cut 1,150 staff in the US
December 8, 2011Research and Development, Sales and Marketing AstraZeneca, cuts
AstraZeneca will cut around 1,150 positions in the US as large patent expiries loom. The cuts will come primarily from …
AstraZeneca to freely share drug compounds with UK groups
December 5, 2011Research and Development, Sales and Marketing AstraZeneca, research
AstraZeneca will make 22 of its compounds available free of charge to UK academia next year as part of a …
Onglyza cleared for use with insulin
November 29, 2011Sales and Marketing AstraZeneca, Merck, Onglyza, diabetes, insulin
European regulators have approved a licence extension for Bristol-Myers Squibb and AstraZeneca’s type II diabetes treatment Onglyza. The oral DPP-4 …
AstraZeneca appoints two new senior leaders in its Americas division
November 22, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca
AstraZeneca has appointed Rich Fante as regional vice president of the Americas, and Marion McCourt as chief operating officer of …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
